Literature DB >> 21681500

Clinical implications of interleukin-18 levels in pediatric patients with Mycoplasma pneumoniae pneumonia.

Tomohiro Oishi1, Mitsuo Narita, Kou Matsui, Takahiro Shirai, Mai Matsuo, Jun Negishi, Takayuki Kaneko, Shinya Tsukano, Tetsuo Taguchi, Makoto Uchiyama.   

Abstract

The immunological pathogenesis of Mycoplasma pneumoniae pneumonia is known to involve several cytokines. The serum levels of interleukin-18 (IL-18) were examined using enzyme-linked immunosorbent assay in 23 pediatric patients (median age 6 years; range 4-13 years; 14 girls and 9 boys) with M. pneumoniae pneumonia admitted to our hospital. Serum levels of IL-18 ranged from 22 to 1808 pg/ml with a mean of 543 pg/ml. We started steroid therapy in two cases with IL-18 values greater than 1000 pg/ml without being aware of IL-18 levels. Examination of associations between IL-18 levels determined by enzyme-linked immunosorbent assay and a routine laboratory test showed that levels of lactate dehydrogenase (LDH) and IL-18 were significantly correlated. To determine the appropriateness of steroid administration in M. pneumoniae pneumonia patients, serum LDH should be examined. Patients with elevated levels of LDH are likely to have significantly elevated IL-18 values (≥1000 pg/ml) and thus can be candidates for steroid therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681500     DOI: 10.1007/s10156-011-0265-7

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  17 in total

1.  Pinocembrin Relieves Mycoplasma pneumoniae Infection‑Induced Pneumonia in Mice Through the Inhibition of Oxidative Stress and Inflammatory Response.

Authors:  JinMing Qian; Mei Xue
Journal:  Appl Biochem Biotechnol       Date:  2022-08-02       Impact factor: 3.094

Review 2.  Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and Management.

Authors:  Lin Tong; Shumin Huang; Chen Zheng; Yuanyuan Zhang; Zhimin Chen
Journal:  J Clin Med       Date:  2022-05-17       Impact factor: 4.964

3.  Predictive value of C-reactive protein in response to macrolides in children with macrolide-resistant Mycoplasma pneumoniae pneumonia.

Authors:  Young Ho Seo; Jang Su Kim; Sung Chul Seo; Won Hee Seo; Young Yoo; Dae Jin Song; Ji Tae Choung
Journal:  Korean J Pediatr       Date:  2014-04-30

Review 4.  Epidemiology of Mycoplasma pneumoniae Infections in Japan and Therapeutic Strategies for Macrolide-Resistant M. pneumoniae.

Authors:  Tsutomu Yamazaki; Tsuyoshi Kenri
Journal:  Front Microbiol       Date:  2016-05-23       Impact factor: 5.640

Review 5.  Classification of Extrapulmonary Manifestations Due to Mycoplasma pneumoniae Infection on the Basis of Possible Pathogenesis.

Authors:  Mitsuo Narita
Journal:  Front Microbiol       Date:  2016-01-28       Impact factor: 5.640

6.  Decreased Interleukin-10 Responses in Children with Severe Mycoplasma pneumoniae Pneumonia.

Authors:  Shenggang Ding; Xiaowu Wang; Wei Chen; Yuan Fang; Boyu Liu; Yan Liu; Guanghe Fei; Linding Wang
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

7.  Hemophagocytic Syndrome Associated with Mycoplasma pneumoniae Pneumonia.

Authors:  Yuji Koike; Nao Aoki
Journal:  Case Rep Pediatr       Date:  2013-07-18

8.  Increased risk of refractory Mycoplasma pneumoniae pneumonia in children with atopic sensitization and asthma.

Authors:  Jeong Eun Shin; Bo Ram Cheon; Jae Won Shim; Deok Soo Kim; Hae Lim Jung; Moon Soo Park; Jung Yeon Shim
Journal:  Korean J Pediatr       Date:  2014-06-30

9.  The Clinical Characteristics and Predictors of Refractory Mycoplasma pneumoniae Pneumonia in Children.

Authors:  Yuanyuan Zhang; Yunlian Zhou; Shuxian Li; Dehua Yang; Xiling Wu; Zhimin Chen
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

10.  Relationships between Th1/Th2 cytokine profiles and chest radiographic manifestations in childhood Mycoplasma pneumoniae pneumonia.

Authors:  Jiu-Ling Zhao; Xin Wang; Yu-Shui Wang
Journal:  Ther Clin Risk Manag       Date:  2016-11-11       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.